Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.94 |
| ▸ | HPGD | P15428 | 5/20 | 0.94 |
| ▸ | GLA | P06280 | 5/20 | 0.94 |
| ▸ | GAA | P10253 | 5/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | HTT | P42858 | 1/20 | 0.94 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.77 |
| ▸ | HTR3A | P46098 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | HK1 | P19367 | 1/20 | 0.65 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547000 | 1.00 | KDM4E (0.94) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL3641196 | 0.98 | KDM4E (0.97) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL30513776 | 0.87 | HRH4 (1.00) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11741104 | 0.87 | HRH4 (1.00) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL30575992 | 0.85 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDGLAGAA | |
| Hydrochloric Acid SCHEMBL11738196 | 0.85 | HRH4 (0.97) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11739391 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1083762 | 0.85 | RAB9A (0.77) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11817813 | 0.85 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1083783 | 0.84 | HTR3A (0.73) | KDM4EALDH1A1HPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210137960-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| WO-2019152808-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2019-08-08 | — | — | WO | disclosed |
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
| US-3980650-A | 4-Amino-pyrimidine derivatives | N.V. KONINKLIJKE PHARMACEUTISCHE FABRIEKEN V/H BROCADES-STHEEMAN EN PHARMACIA (NL) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137960-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES | KPNA1, KPNA2, KPNB1 | KDM4E 2419/4885ALDH1A1 4862/4885HPGD 4656/4885 |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | PARP15, PAPSS1, PGA5 | KDM4E 3106/4885ALDH1A1 2051/4885HPGD 1413/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | KDM4E 4510/4885ALDH1A1 1210/4885HPGD 2640/4885 |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | KDM4E 3106/4885ALDH1A1 2051/4885HPGD 1413/4885 |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | KDM4E 1876/4885ALDH1A1 1860/4885HPGD 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.